Clinical pharmacokinetics of digoxin
- PMID: 322907
- DOI: 10.2165/00003088-197702010-00001
Clinical pharmacokinetics of digoxin
Abstract
About 70 to 80% of an oral dose of digoxin is absorbed, mainly in the proximal part of the small intestine. The degree of binding to serum albumin is 20 to 30%. Digoxin is extensively distributed in the tissues, as reflected by the large volume of distribution. High concentrations are found in the heart and kidneys, but the skeletal muscles form the largest digoxin storage. The half-life of elimination in healthy persons varies between 26 and 45 hours. The main route of elimination is renal excretion of digoxin, which is closely correlated with the glomerular filtration rate. In addition, some tubular secretion and perhaps tubular reabsorption occurs. Nearly all of the digoxin in the urine is excreted unchanged, with a small part as active metabolites. The clinical significance of dihydrodigoxin as a metabolite remains to be resolved. About 25 to 28% of digoxin is eliminated by nonrenal routes. Biliary excretion may rise up to 30% of a given dose, but the enterohepatic cycle seems to be of minor importance. The pharmacodynamic effects of digoxin, including toxic symptoms, are correlated with the uptake of digoxin in the heart after a single dose and with the steady state serum digoxin concentration during maintenance therapy. Impaired kidney function is the most important condition with an influence on the pharmacokinetics of digoxin. In addition to the renal clearance of creatinine, the biovailability of the digoxin formulation used, the volume of distribution, the amount of extrarenal clearance, body weight and serum albumin concentration, are other factors which may modify the serum level of digoxin. Certain drug interactions may also occur during the absorptive phase. Exact prediction of serum digoxin concentrations by various dosage calculations has not succeeded. Since many factors may influence the sensitivity of the myocardium to digoxin, measurement of serum digoxin levels in only one, but a useful criterion, when making clinical decisions about adjustment of digoxin dosage.
Similar articles
-
Clinical pharmacokinetics of digoxin in infants.Clin Pharmacokinet. 1977 Jan-Feb;2(1):17-31. doi: 10.2165/00003088-197702010-00002. Clin Pharmacokinet. 1977. PMID: 322908 Review.
-
Changes in steady state digoxin pharmacokinetics during quinidine therapy in cardiac patients: influence of plasma quinidine concentration.Acta Pharmacol Toxicol (Copenh). 1983 May;52(5):357-63. doi: 10.1111/j.1600-0773.1983.tb01115.x. Acta Pharmacol Toxicol (Copenh). 1983. PMID: 6880771
-
Digoxin pharmacokinetics and dosage requirements in pediatric patients.Clin Pharm. 1983 May-Jun;2(3):224-35. Clin Pharm. 1983. PMID: 6349908 Review.
-
The development and application of a radioimmunoassay for dihydrodigoxin, a digoxin metabolite.J Pharmacol Exp Ther. 1982 Apr;221(1):123-31. J Pharmacol Exp Ther. 1982. PMID: 7062278
-
Clinical pharmacokinetics of amiodarone.Clin Pharmacokinet. 1984 Mar-Apr;9(2):136-56. doi: 10.2165/00003088-198409020-00002. Clin Pharmacokinet. 1984. PMID: 6370540 Review.
Cited by
-
Haemoperfusion in the management of digoxin toxicity: is it warranted?Clin Pharmacokinet. 1979 Sep-Oct;4(5):395-9. doi: 10.2165/00003088-197904050-00005. Clin Pharmacokinet. 1979. PMID: 509853
-
Therapeutic drug monitoring of antiarrhythmic drugs.Clin Pharmacokinet. 2003;42(7):647-63. doi: 10.2165/00003088-200342070-00004. Clin Pharmacokinet. 2003. PMID: 12844326 Review.
-
Evaluation of a Potential Clinical Significant Drug-Drug Interaction between Digoxin and Bupropion in Cynomolgus Monkeys.Pharm Res. 2018 Nov 6;36(1):1. doi: 10.1007/s11095-018-2525-z. Pharm Res. 2018. PMID: 30402714
-
Differences in kinetic properties of drugs: implications as to the selection of a particular drug for use in patients with renal failure with special emphasis on antibiotics and beta-adrenoceptor blocking agents.Clin Pharmacokinet. 1980 Sep-Oct;5(5):441-64. doi: 10.2165/00003088-198005050-00003. Clin Pharmacokinet. 1980. PMID: 6105934
-
Intermittent low-dose digoxin may be effective and safe in patients with chronic heart failure undergoing maintenance hemodialysis.Exp Ther Med. 2014 Dec;8(6):1689-1694. doi: 10.3892/etm.2014.2013. Epub 2014 Oct 9. Exp Ther Med. 2014. PMID: 25371716 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources